Keytrudaと同じケモ併用でこんなデータもありますよ
オプジーボ＋ケモ 2年生存率62％
Journal of Clinical Oncology
Nivolumab in Combination With Platinum‐Based Doublet Chemotherapy
for First-Line Treatment of Advanced Non–Small-Cell Lung Cancer
<<Naiyer A. Rizvi and Matthew D. Hellmann, Memorial Sloan Kettering Cancer Center>>
Encouraging activity was observed, especially for the nivolumab 5 mg/kg plus paclitaxel-carboplatin group,with a 2-year OS rate of 62%
Keytrudaと同じケモ併用でこんなデータもありますよ
オプジーボ＋ケモ 2年生存率62％
Journal of Clinical Oncology
Nivolumab in Combination With Platinum‐Based Doublet Chemotherapy
for First-Line Treatment of Advanced Non–Small-Cell Lung Cancer
<<Naiyer A. Rizvi and Matthew D. Hellmann, Memorial Sloan Kettering Cancer Center>>
Encouraging activity was observed, especially for the nivolumab 5 mg/kg plus paclitaxel-carboplatin group,with a 2-year OS rate of 62%